TLDR: Brevis introduces ZK verification that supports rapid execution while keeping trading flows fully trustless and verifiable. AsterDEX integrates Brevis’ ZKTLDR: Brevis introduces ZK verification that supports rapid execution while keeping trading flows fully trustless and verifiable. AsterDEX integrates Brevis’ ZK

Brevis Partners With AsterDEX to Bring Verifiable ZK Security to Perps and Spot Trading

2025/12/12 15:03
3 min read

TLDR:

  • Brevis introduces ZK verification that supports rapid execution while keeping trading flows fully trustless and verifiable.
  • AsterDEX integrates Brevis’ ZK stack to unify CEX-grade performance with dependable on-chain guarantees for traders.
  • The collaboration protects position-level data through privacy layers without affecting market-wide transparency metrics.
  • Both teams aim to create an architecture ready for institutional-grade activity across perpetuals and spot markets.

Brevis has partnered with AsterDEX to introduce verifiable ZK security and improved privacy to perpetuals and spot markets. 

The collaboration is structured to address the performance ceiling that has shaped decentralized trading for years.

ZK Verification Targets Speed and Privacy Gaps in On-Chain Trading

Brevis explained that DEXs continue to face a barrier where faster execution often weakens trustless design. 

Full on-chain processing slows trade performance and removes privacy for active positions. Traders have been required to accept either centralized speed or decentralized protections, a choice that has limited broader adoption.

According to the company’s announcement, its ZK-powered compute system is designed to remove this tradeoff. 

Execution can occur at speeds similar to centralized platforms, while cryptographic verification follows within seconds. This model keeps the trust layer intact without slowing active trading flows on perpetuals and spot markets.

Brevis also stated that its privacy layer can shield position-level data while maintaining clarity on overall market metrics. 

This structure supports traders who need confidentiality without obstructing transparent oversight. The post from Brevis added that speed, security, and privacy no longer need to work against one another when ZK verification sits behind the engine.

AsterDEX Integrates Brevis ZK Tech for a Unified Trading Architecture

AsterDEX confirmed the partnership in its own update, noting that the integration of Brevis’ ZK infrastructure with its trading engine is intended to push decentralized trading beyond its current limits. 

The exchange said the new system brings CEX-level performance together with on-chain guarantees in a single architecture.

The team emphasized that this framework is built to serve both retail and institutional participants. With Brevis providing the verification and privacy stack, AsterDEX aims to deliver rapid execution on perpetuals and spot pairs while keeping market operations fully verifiable.

Both companies described the initiative as a foundation for the next phase of decentralized exchange growth. 

AsterDEX stated that its engine is already redefining market performance, and the addition of Brevis ZK technology will help maintain the balance between speed and cryptographic assurance.

The collaboration positions Brevis’ verifiable ZK system at the center of AsterDEX’s upgraded trading environment. Together, the teams are building an on-chain model where execution, privacy, and verification operate in alignment rather than forcing traders to choose between them.

The post Brevis Partners With AsterDEX to Bring Verifiable ZK Security to Perps and Spot Trading appeared first on Blockonomi.

Market Opportunity
ZKsync Logo
ZKsync Price(ZK)
$0.02146
$0.02146$0.02146
-0.23%
USD
ZKsync (ZK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26